Biomics Technologies Co. Ltd

Biomics Technologies Co. Ltd, funded in 2006, is one of the world's very few companies having the integrated technologies of full-sites siRNA library construction, high-throughput RNA drug targets identification, siRNA structure modification and drug delivery systems. It owns a series of intellectual properties on RNAi technology and a few candidates are in the process of pre-clinical study, of which, Age-related Macular Degeneration (AMD) will be in Phase I study very soon. It also provides services for gene therapeutic researches including: siRNA large scale synthesis, high throughput RNAi target screening, oligo modification etc.